Document is current

Article History

Received: 25 July 2025

Accepted: 29 August 2025

First Online: 11 September 2025

Declarations

:

: Ricardo Ruiz-Villaverde declares that he has received funding for attendance at meetings and conferences, speaker fees and funding for participating in research from Almirall, Sunpharma, Celgene, Leo-Pahrma, Sanofi, Abbvie, Lilly, Novartis, Galderma, Pfizer, UCB Pharma and Janssen. Almudena Mateu has potential conflict of interests (advisory board member, consultant, research support, participation in clinical trials and honorary for speaking) with the following pharmaceutical companies AbbVie, Almirall SA, Celgene, Jansen-Cilag, Leo-Pharma, Lilly, Novartis and Pfizer. Pedro Mendes-Bastos has received consultancy and/or speaker’s honoraria from and/or participated in clinical trials sponsored by Lilly, AbbVie, Alumis, Johnson & Johnsson Innovative Medicine, Novartis, LEO Pharma, Almirall, Sanofi, Regeneron, Viatris, Pierre Fabre, L’Oréal, Organon, Evelo Biosciences, CS Portugal, Pfizer, Biogen, Apogee Therapeutics and Amgen. Tiago Torres has received consultancy and/or speaker’s honoraria from and/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, Apogee Therapeutics, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Johnson & Johnson Innovative Medicine, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz, STADA and UCB. Tiago Torres is an Editorial Board member of Dermatology and Therapy. Tiago Torres was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.